Photo taken from nature.com
Apr 2, 2024, 05:37
Paolo Tarantino: The OXEL trial is out on Nature Communications
Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
“The OXEL trial, led by Filipa Lynce, is out on Nature Communications. Among 45 pts with residual TNBC after NAT, adjuvant Nivolumab/Capecitabine were well tolerated, increased peripheral immune score and led to numerically improved 2 year iDFS (91%) vs nivo (47%) or cape alone (53%). “
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18
Dec 21, 2024, 11:12
Dec 21, 2024, 11:06
Dec 21, 2024, 10:38